alexa Choosing to Treat Membranous Nephropathy: A 30-year Experience | OMICS International | Abstract
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Choosing to Treat Membranous Nephropathy: A 30-year Experience

Mary Carla Estevez Diz and Gianna Mastroianni Kirsztajn*

Glomerulopathy Section, Division of Nephrology, Department of Medicine, Federal University of Sao Paulo (UNIFESP), Brazil

*Corresponding Author:
Prof. Gianna Mastroianni Kirsztajn
Disciplina de Nefrologia
Universidade Federal de São Paulo (UNIFESP)
Rua Botucatu, n. 740, CEP 04023-900
São Paulo-SP, Brazil
Tel: 55-11-5904-1699
Fax: 5904-1684
E-mail: [email protected]

Received Date: April 19, 2012; Accepted Date: May 15, 2012; Published Date: May 17, 2012

Citation: Estevez Diz MC, Kirsztajn GM (2012) Choosing to Treat Membranous Nephropathy: A 30-year Experience. J Nephrol Therapeut S5:001. doi:10.4172/2161-0959.S5-001

Copyright: ©2012 Estevez Diz MC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Membranous nephropathy (MN) is one of the most frequent causes of nephrotic syndrome in adults. The clinical course is variable, and its treatment is still a matter of controversies. The aim of this study was to establish when immunosuppressive (IMS) therapy should be indicated in our population with MN.

Methods: We evaluated retrospectively clinical and laboratorial data from 71 patients with primary MN, followed in the Glomerulopathy Section (UNIFESP), from 1976 to 2006.

Results: Ten of the 71 patients have not received any specific IMS treatment, while the remainders were submitted to several specific therapies. The final mean creatinine in the non-treated (2.0 ± 1.83 mg/dL) was higher than that of the treated group (1.66 ± 1.54 mg/dL) and there was a strong and significant difference between decreases of proteinuria levels in the group of treated patients when compared to the non treated group. The highest frequency of complete remission was observed in the treated patients (22.9% vs. 10% in non treated) and the highest index of non response in the non treated group (60% vs. 41% in treated), but these differences were not statistically significant. When we compared the patients who received oral corticosteroid, or intravenous (IV) methylprednisolone (MP) plus cyclophosphamide (Cyp), and non treated patients, we observed a favorable effect of the IMS treatment, especially of IV MP plus Cyp.

Conclusions: In a long term follow-up of MN patients IMS treatment was associated to better renal outcome, including more frequent remission, lower final proteinuria and serum creatinine.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

bornova escort

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version